Exelixis | EXEL - Cash And Equivalent


Exelixis reported $226.15M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Exelixis USD 226.15M 256.34M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.91B 687M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026